186 related articles for article (PubMed ID: 9421275)
21. Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.
Rivara S; Mor M; Silva C; Zuliani V; Vacondio F; Spadoni G; Bedini A; Tarzia G; Lucini V; Pannacci M; Fraschini F; Plazzi PV
J Med Chem; 2003 Apr; 46(8):1429-39. PubMed ID: 12672242
[TBL] [Abstract][Full Text] [Related]
22. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.
Spadoni G; Balsamini C; Bedini A; Diamantini G; Di Giacomo B; Tontini A; Tarzia G; Mor M; Plazzi PV; Rivara S; Nonno R; Pannacci M; Lucini V; Fraschini F; Stankov BM
J Med Chem; 1998 Sep; 41(19):3624-34. PubMed ID: 9733487
[TBL] [Abstract][Full Text] [Related]
23. Tail arteries from chronically spinalized rats have potentiated responses to nerve stimulation in vitro.
Yeoh M; McLachlan EM; Brock JA
J Physiol; 2004 Apr; 556(Pt 2):545-55. PubMed ID: 14766944
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of melatonin on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats.
Girouard H; de Champlain J
Am J Hypertens; 2004 Apr; 17(4):339-46. PubMed ID: 15062888
[TBL] [Abstract][Full Text] [Related]
25. Effect of oxytocin as a partial agonist at vasoconstrictor vasopressin receptors on the human isolated uterine artery.
Jovanović A; Jovanović S; Tulić I; Grbović L
Br J Pharmacol; 1997 Aug; 121(7):1468-74. PubMed ID: 9257929
[TBL] [Abstract][Full Text] [Related]
26. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor.
Dubocovich ML; Masana MI; Iacob S; Sauri DM
Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):365-75. PubMed ID: 9089668
[TBL] [Abstract][Full Text] [Related]
27. Non-adrenergic inhibition at prejunctional sites by agmatine of purinergic vasoconstriction in rabbit saphenous artery.
Zhao D; Ren LM
Neuropharmacology; 2005 Mar; 48(4):597-606. PubMed ID: 15755487
[TBL] [Abstract][Full Text] [Related]
28. Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery.
Krause DN; Barrios VE; Duckles SP
Eur J Pharmacol; 1995 Apr; 276(3):207-13. PubMed ID: 7601206
[TBL] [Abstract][Full Text] [Related]
29. 2-Phenylmelatonin: a partial agonist at enteric melatonin receptors.
Santagostino-Barbone MG; Masoero E; Spelta V; Lucchelli A
Pharmacol Toxicol; 2000 Oct; 87(4):156-60. PubMed ID: 11097268
[TBL] [Abstract][Full Text] [Related]
30. Receptor-mediated modulation of avian caecal muscle contraction by melatonin: role of tyrosine protein kinase.
Poon AM; Kravtsov GM; Pang SF
J Pineal Res; 2002 Apr; 32(3):199-208. PubMed ID: 12074105
[TBL] [Abstract][Full Text] [Related]
31. [Effects of exogenic noradrenaline and melatonin on the neurogenic vasoreactivity].
Iartsev VN; Karachentseva OV; Dvoretskiĭ DP
Ross Fiziol Zh Im I M Sechenova; 2004 Nov; 90(11):1363-9. PubMed ID: 15646204
[TBL] [Abstract][Full Text] [Related]
32. Sigma receptor ligands inhibit rat tail artery contractile responses by multiple mechanisms.
Massamiri T; Duckles SP
J Pharmacol Exp Ther; 1991 Oct; 259(1):22-9. PubMed ID: 1656019
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic restoration of suppressed temperature rhythms in rats by melatonin, melatonin receptor agonist, S20242, or 8-OH-DPAT.
Deprés-Brummer P; Metzger G; Lévi F
Eur J Pharmacol; 1998 Apr; 347(1):57-66. PubMed ID: 9650848
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a retinal melatonin receptor.
Dubocovich ML
J Pharmacol Exp Ther; 1985 Aug; 234(2):395-401. PubMed ID: 2991499
[TBL] [Abstract][Full Text] [Related]
35. Interactions of minoxidil with vasoconstrictive agents in isolated rat tail artery.
Wasiński R; Godlewski G; Wróbel B; Buckzko W
Acta Pol Pharm; 1995; 52(3):253-6. PubMed ID: 8960256
[TBL] [Abstract][Full Text] [Related]
36. Luzindole (N-0774): a novel melatonin receptor antagonist.
Dubocovich ML
J Pharmacol Exp Ther; 1988 Sep; 246(3):902-10. PubMed ID: 2843633
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores.
Teh MT; Sugden D
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):522-8. PubMed ID: 9840420
[TBL] [Abstract][Full Text] [Related]
38. Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study.
Spadoni G; Balsamini C; Diamantini G; Di Giacomo B; Tarzia G; Mor M; Plazzi PV; Rivara S; Lucini V; Nonno R; Pannacci M; Fraschini F; Stankov BM
J Med Chem; 1997 Jun; 40(13):1990-2002. PubMed ID: 9207940
[TBL] [Abstract][Full Text] [Related]
39. [Selective augmenting effect of oxy-Hb on the contractions of cerebral arteries elicited by various vasoactive substances].
Tsuiki K
No Shinkei Geka; 1988 Sep; 16(10):1155-62. PubMed ID: 2905026
[TBL] [Abstract][Full Text] [Related]
40. Plasma 6-hydroxymelatonin, 6-sulfatoxymelatonin and melatonin kinetics after melatonin administration to rats.
Raynaud F; Mauviard F; Geoffriau M; Claustrat B; Pevet P
Biol Signals; 1993; 2(6):358-66. PubMed ID: 8038864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
